Actovegin equal to performance enhancing drug doping: fact or fiction? by Lee, Paul et al.
Volume 7 • Issue 3 • 1000179J Tissue Sci Eng, an open access journalISSN: 2157-7552
Short Communication OMICS International
Journal of 
Tissue Science & EngineeringJourn
al
 o
f T
iss
ue S
cience & Engineering
ISSN: 2157-7552
Lee et al., J Tissue Sci Eng 2016, 7:3
DOI: 10.4172/2157-7552.1000179
Introduction
Actovegin is a biological drug that has been used for the treatment 
of sports muscle injuries. Several in vitro studies have shed light 
on potential mechanisms of action and the drug has consistently 
demonstrated its potential to reduce return from injury time for 
muscle tears in elite athletes. Yet it was banned for a time under the 
International Olympic Committee (IOC) as a blood doping agent, this 
ban was based on presumptuous conclusions and subsequently lifted 
after no indisputable evidence could be provided. This editorial aims 
to provide readers with some of the key, objective facts relating to 
Actovegin and then based on this, will offer an infromed opinion on 
its role in sports medicine. We also hope to highlight the importance 
of evidence-based medicine, particularly in the volatile field of Sports 
Medicine, and the need for facts, not fiction.
Actovegin
Actovegin (Takeda Pharmaceutical Company Ltd, Osaka, Japan) is 
a biological drug produced from deproteinised haemodialysate of calf 
serum. Its high standard of quality control and long 50-year history of 
clinical evidence has provided much evidence to support its efficacy 
[1]. Functioning in a similar vain to other calf blood derivatives, it can 
be compared to foetal bovine serum (FBS) which is well known for its 
established role in maintaining cell viability in in vitro tissue culture 
methods. Thus, Actovegin may be considered as a highly controlled and 
approved form of FBS with an excellent track record for human use in 
the clinical setting.
In Vitro Evidence
The active component and mechanism of Actovegin has yet to be 
identified, its effects are likely due to a mixture of ingredients instead 
of a single active compound. Study has shown the drug to not contain 
peptide, growth factor or hormone-like substances [2]. Further, in vitro 
evidence suggests that Actovegin promotes oxidative metabolism and 
shifts the redox-balance of cells to produce more oxidized substrates, 
possibly protecting against hypoxic cell injury [2]. This mechanism 
can be logically extrapolated to the first few hours of muscle injury 
where the goal of any therapeutic intervention would be to interrupt 
the process of cell damaging events, and therefore importantly preserve 
cell viability at the injury site. In vitro evidence has also pointed 
towards Actovegin’s protective effect on injured cell types ranging from 
neuroblastoma cells [3], neutrophils [4] and renal cells [5]. It has also 
been postulated that Actovegin could have a beneficial effect as an 
injective therapy for osteoarthritis [6].
One of the properties of Actovegin is to promote oxidation and 
energy production in cell cultures, its efficacy is assumed to benefit 
post-ischemic metabolic events clinically. A recent in vitro study 
has made unsubstantiated, optimistic claims about the potential 
performance enhancing qualities of Actovegin for clinical use [7]. 
Søndergård et al. inflicted cell membrane injuries to the muscle cells 
with a cytotoxic detergent, Saponin then treated the cell culture with 
Actovegin and analysed mitochondrial activity of the cells. They 
concluded that as the Actovegin groups had higher mitochondrial 
activity, it must be able to enhance sports performance and failed to 
consider the fact that Actovegin may also have membrane stabilizing 
properties which stabilized cells and allowed the mitochondria to 
function normally. As discussed in the previous section, Actovegin 
is a drug that has been proven to have protective effects on ischemic 
cells. Therefore, it is important that we highlight here that the study 
by Søndergård et al. should be viewed as an in vitro cell membrane 
injury study and not a performance analysis. Care must be taken when 
extrapolating conclusions from in vitro evidence, as results will not 
necessarily translate. In fact more care must be taken in concluding 
whether or not any substance will improve performance in humans 
from in vitro studies. This misleading conclusion may have contributed 
to the fictitious hype with article exposure and media attention, thus 
having a detrimental effect on science and medical research. 
Legality and Ergogenic Potential
In December, 2000, the IOC banned the use of Actovegin as an 
ergogenic substance after noting its prolific use at the Sydney Olympic 
Games and that year’s Tour de France [8]. The ban was lifted however, 2 
months later after no indisputable evidence was provided demonstrating 
Actovegin had performance enhancing potential. The current stance 
from World Anti Doping Agency (WADA) is that Actovegin is legal 
under 50 mL every 6 h. However, 50 mL is 25 fold higher than the 
amount injected for a muscle tear and that is without concentrating the 
drug; making these guidelines somewhat ill-informed. Further, neither 
intravenous nor intramuscular injections of Actovegin are prohibited 
in or out of competition according to latest search in Global Drug 
Reference Online, which is approved by UK Anti-Doping (UKAD), the 
Canadian Centre for Ethics in Sport (CCES), the United States Anti-
Doping Agency (USADA) and WADA [9,10].
A study of 567 diabetic patients showed no improvement in muscle 
strength or condition was found after maximal Actovegin infusion 
for 160 days [11]. Further, Lee et al. performed another, more recent 
blinded, crossover peak aerobic capacity study in healthy human 
participants [12]. Lee et al. provide definitive clinical evidence that 
Actovegin did not improve aerobic capacity compared to saline control 
in humans. No significant differences were observed in peak values 
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for aerobic power. Additionally, values of gross and net efficiency, and 
calorific energy equivalents associated with VO2 were similar. Therefore, 
in brief, results from this study provide definitive clinical evidence that 
Actovegin in its maximum permitted dose does not improved human 
peak aerobic capacity. Thus, showing the claims by Sondergard et al. do 
not extrapolate to a human population. Interestingly, in a recent series 
of studies with human macrophages using RT-PCR and flow cytometry, 
they have tentatively demonstrated a possible role of Actovegin as an 
anti-inflammatory agent, which is consistent with the finding that 
Actovegin can reduce the recovery time in mild muscle injuries.
Muscle Injuries - Current Strategies and Issues
Muscle injuries are common in sports, recently different injection 
treatment options such as growth factors have demonstrated encouraging 
results, however, with their anabolic properties, interventions that 
utilize growth factors, autologous blood or autologous conditioned 
serum are unfeasible therapeutic options for professional athletes, being 
banned by WADA [10]. Interventions such as Platelet Rich Plasma 
(PRP) and Autologous Conditioning Serum (ACS) have become 
popular augmentative therapies in Sports Medicine, being proposed 
to facilitate muscle healing by optimizing provision of growth factors 
from promising animal study [13-15]. However, again these results 
do not necessarily translate to human trial. Reurink et al. in a recent, 
double-blind, randomized placebo controlled trial, showed no clinical 
or statistical difference between PRP and placebo treated groups [15]. 
This study did highlight the heterogeneity in PRP preparation protocol, 
distinct lack of consistency in quality control and thus, variation 
between individual PRP injections. This is an issue we as authors have 
highlighted previously [6]. The information thus suggests that there is 
a lack of an effective, legally utilizable option for professional athletes 
to treat acute muscle injuries. It also dictates that that use of blood 
products as biological drugs for muscular injury is nothing new and the 
Actovegin is a logical option.
Clinical Evidence
The use of Actovegin as an intramuscular injection therapy for 
acute muscle tears was first documented by Pfister and Koller [16]. 
They reported a reduction in recovery time from 8.3 weeks to 5.5 
weeks in treatment groups. However, their partially blinded case 
control study of 103 patients received several criticisms. Patients were 
recruited from different levels of sport and thus treatment regime 
and rehabilitation protocols were therefore not standardised. Further, 
Actovegin was mixed with local anaesthetic, which could have altered 
its pharmacodynamic and kinetic properties. Finally, the outcome 
scores were made on subjective observation by patients and clinicians 
with no pre-injury data to compare with.
Since this study there has been limited supporting evidence for its 
role in the treatment of muscle injuries. Lee et al. have published a study 
on the effects of standalone Actovegin therapy, reporting a reduction in 
return to play time in injured, professional footballers of 8 days when 
compared to physiotherapy alone (p=0.033) [17]. This study using 
players from the same elite football club allowed for standardization of 
intervention, physical fitness and rehabilitation protocols. 
Conclusion
The evidence provided in this editorial delivers updated evidence 
that hopefully can dispel the shroud of criticism that has surrounded 
Actovegin. The in vitro evidence provides insight into the mechanism 
by which this biological drug is improving cell oxidative metabolism 
and its role in shifting redox balance to maintain cell viability. The 
clinical evidence provided has highlighted the importance of care in 
extrapolating in vitro findings, which do not necessarily extrapolate 
clinically. Further, clinical evidence has demonstrated  that standalone 
Actovegin therapy is safe and effective to treat muscle injuries in 
elite sports professionals [17]. It is important therefore, particularly 
in a volatile field such as Sports Medicine, that an evidence based 
medicine approach is taken throughout and treatments are not judged 
on anecdotal and subjective opinion. Current evidence is suggestive 
that Actovegin is a non-ergogenic, safe and potentially beneficial 
biological drug for the treatment of sports related muscle injury in elite 
athletes. Further research will tease out mechanisms and identify active 
ingredients, while clinical trials could confirm efficacy and establish a 
dose-response relationship. We should remain cautious in generating 
facts over anecdotal fiction and tailor the use of any intervention to an 
individual athlete’s need above anything else.
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